CN110139659B - 用于治疗干燥综合征的肽 - Google Patents

用于治疗干燥综合征的肽 Download PDF

Info

Publication number
CN110139659B
CN110139659B CN201880005934.0A CN201880005934A CN110139659B CN 110139659 B CN110139659 B CN 110139659B CN 201880005934 A CN201880005934 A CN 201880005934A CN 110139659 B CN110139659 B CN 110139659B
Authority
CN
China
Prior art keywords
expression
peptide
certain embodiments
activity
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201880005934.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110139659A (zh
Inventor
E·莫泽斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of CN110139659A publication Critical patent/CN110139659A/zh
Application granted granted Critical
Publication of CN110139659B publication Critical patent/CN110139659B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201880005934.0A 2017-01-05 2018-01-04 用于治疗干燥综合征的肽 Expired - Fee Related CN110139659B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762442441P 2017-01-05 2017-01-05
US62/442,441 2017-01-05
US201762481702P 2017-04-05 2017-04-05
US62/481,702 2017-04-05
US201762557153P 2017-09-12 2017-09-12
US62/557,153 2017-09-12
PCT/IL2018/050012 WO2018127914A1 (en) 2017-01-05 2018-01-04 Peptides for treating sjogren's syndrome

Publications (2)

Publication Number Publication Date
CN110139659A CN110139659A (zh) 2019-08-16
CN110139659B true CN110139659B (zh) 2023-07-28

Family

ID=61157250

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880005934.0A Expired - Fee Related CN110139659B (zh) 2017-01-05 2018-01-04 用于治疗干燥综合征的肽

Country Status (8)

Country Link
US (1) US11167005B2 (enExample)
EP (1) EP3565574A1 (enExample)
JP (1) JP7242059B2 (enExample)
CN (1) CN110139659B (enExample)
AU (1) AU2018205885A1 (enExample)
CA (1) CA3047706A1 (enExample)
IL (1) IL267426B2 (enExample)
WO (1) WO2018127914A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116287183B (zh) * 2022-11-18 2023-11-03 中国医学科学院北京协和医院 一组用于诊断干燥综合征的分子标志物组合

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1503806A (zh) * 2001-02-26 2004-06-09 Ү���о�����չ���޹�˾ 用于治疗系统性红斑狼疮的16/6id抗体肽
CN101035554A (zh) * 2004-08-23 2007-09-12 维兹曼科学研究所耶达研究与发展有限公司 介导应激反应的肽抑制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613536B1 (en) 1995-03-28 2003-09-02 Yeda Research And Development Co. Ltd. Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
WO2004064788A2 (en) 2003-01-14 2004-08-05 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
CN1774259B (zh) * 2003-01-14 2011-12-28 特瓦制药工业有限公司 治疗系统性红斑狼疮的肽的胃肠道外制剂
NZ597082A (en) * 2005-10-13 2013-11-29 Human Genome Sciences Inc Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
WO2008087647A2 (en) 2007-01-19 2008-07-24 Yeda Research And Development Co. Ltd. Methods of diagnosing, monitoring treatment and treating systemic lupus erythematosus (sle)
WO2014052393A2 (en) * 2012-09-25 2014-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for the diagnosis and treatment of sjögren's syndrome
US20180043017A1 (en) 2016-08-11 2018-02-15 Xtl Biopharmaceuticals Ltd. Pharmaceutical compositions comprising 0.5 mg dose of synthetic human peptides for treating systemic lupus erythematosus
US20180043016A1 (en) 2016-08-11 2018-02-15 Xtl Biopharmaceuticals Ltd. Pharmaceutical compositions comprising 0.25 mg dose of synthetic human peptides for treating systemic lupus erythematosus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1503806A (zh) * 2001-02-26 2004-06-09 Ү���о�����չ���޹�˾ 用于治疗系统性红斑狼疮的16/6id抗体肽
CN101035554A (zh) * 2004-08-23 2007-09-12 维兹曼科学研究所耶达研究与发展有限公司 介导应激反应的肽抑制剂

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus;Mozes E等;《Autoimmunity reviews》;20100723;第10卷(第1期);22-26 *
Brito-Zeron P等.Sjögren syndrome.《Nature reviews Disease primers》.2016,第2卷(第1期),16047. *
XTL Biopharmaceuticals Ltd.BRIEF-XTL Biopharmaceuticals unveils expanded HCDR1 preclinical data for treatment of sjögren"s syndrome.《网页》.2017,https://www.prnewswire.com/news-releases/xtl-biopharmaceuticals-unveils-additional-expanded-hcdr1-preclinical-data-for-the-treatment-of-sjogrens-syndrome-300517922.html. *
XTL Biopharmaceuticals Unveils Additional Expanded hCDR1 Preclinical Data for the Treatment of Sjogren"s Syndrome;XTL Biopharmaceuticals Ltd;《网页》;20180326;https://www.reuters.com/article/brief-xtl-biopharmaceuticals-unveils-exp-idUSFWN1HD0JG *

Also Published As

Publication number Publication date
AU2018205885A1 (en) 2019-06-27
IL267426B1 (en) 2023-11-01
CA3047706A1 (en) 2018-07-12
US11167005B2 (en) 2021-11-09
IL267426A (en) 2019-08-29
IL267426B2 (en) 2024-03-01
US20190351004A1 (en) 2019-11-21
JP7242059B2 (ja) 2023-03-20
CN110139659A (zh) 2019-08-16
JP2020505324A (ja) 2020-02-20
WO2018127914A1 (en) 2018-07-12
EP3565574A1 (en) 2019-11-13

Similar Documents

Publication Publication Date Title
Schall et al. Peptide-based approaches to treat lupus and other autoimmune diseases
CN105705160B (zh) Il-22二聚体在制备用于治疗胰腺炎的药物中的用途
JP2019065053A (ja) α−メラニン形成細胞刺激ホルモンのペプチド類似体
WO2010070047A1 (en) Soluble polypeptides for use in treating autoimmune and inflammatory disorders
AU2023233094B2 (en) Anti-inflammatory agents
WO2015138638A1 (en) Long acting trail receptor agonists for treatment of autoimmune diseases
CN110139659B (zh) 用于治疗干燥综合征的肽
JP2007500693A (ja) 移植片拒絶反応を予防するための合成ペプチドコポリマーを含む併用療法
CN112512640A (zh) Cd24用于预防和治疗移植物抗宿主病和粘膜炎的使用方法
JP2021514183A (ja) 改変免疫調節ペプチド
JP2003507011A (ja) Ｉｌ−１６拮抗剤
Briand et al. Emerging peptide therapeutics for inflammatory autoimmune diseases
CN107106643A (zh) 在癌症或癌转移的治疗或预防中的环状乙酰胆碱酯酶c端肽
HK40012327A (en) Peptides for treating sjogren's syndrome
US9617325B2 (en) Treatment of IgE-mediated disease
EP4304626A1 (en) Trem-1 inhibitors for the treatment of marfan syndrome
WO2008037497A2 (en) Galectin-2 for the treatment of inflammatory diseases of the skin
EP4445910A1 (en) Vaccine composition for inducing anti-il-23 antibody
CN107896494A (zh) 多肽组合物
US20200360484A1 (en) Ndp-msh for treatment of inflammatory and/or neurodegenerative disorders of the cns
WO2024030950A2 (en) Compositions for the treatment of disease
WO2006052773A2 (en) Treatments for demyelinating immune mediated diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40012327

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20230728

CF01 Termination of patent right due to non-payment of annual fee